First Nebraska Trust Co Acquires New Holdings in Merck & Co., Inc. $MRK

Key Points

• First Nebraska Trust Co. acquired 104,203 Merck shares worth approximately $12.5 million in the first quarter, making Merck its 20th-largest holding and representing 1.2% of its portfolio. Institutional investors collectively own 76.07% of MRK.
• Merck’s growth outlook is supported by Keytruda lifecycle extensions, pipeline progress and recent acquisitions, while analysts maintain a constructive view with a “Moderate Buy” consensus and an average price target of $134.50.
• Investors are focused on Merck’s upcoming second-quarter results, with Gardasil weakness, acquisition costs and valuation posing risks despite a recently declared $0.85 quarterly dividend and an approximately 2.6% annualized yield.

First Nebraska Trust Co acquired a new position in Merck & Co., Inc. (NYSE:MRK - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 104,203 shares of the company's stock, valued at approximately $12,535,000. Merck & Co., Inc. accounts for approximately 1.2% of First Nebraska Trust Co's investment portfolio, making the stock its 20th biggest holding.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRK. Chesapeake Wealth Management raised its position in shares of Merck & Co., Inc. by 0.6% during the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company's stock worth $1,552,000 after buying an additional 87 shares in the last quarter. South Plains Financial Inc. boosted its holdings in shares of Merck & Co., Inc. by 0.6% in the fourth quarter. South Plains Financial Inc. now owns 15,535 shares of the company's stock valued at $1,635,000 after acquiring an additional 89 shares in the last quarter. Syverson Strege & Co boosted its holdings in shares of Merck & Co., Inc. by 2.2% in the fourth quarter. Syverson Strege & Co now owns 4,142 shares of the company's stock valued at $436,000 after acquiring an additional 90 shares in the last quarter. Nations Financial Group Inc. IA ADV increased its stake in shares of Merck & Co., Inc. by 0.4% during the first quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company's stock valued at $2,819,000 after acquiring an additional 91 shares during the period. Finally, Westside Investment Management Inc. increased its stake in shares of Merck & Co., Inc. by 3.1% during the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company's stock valued at $331,000 after acquiring an additional 93 shares during the period. Institutional investors own 76.07% of the company's stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s launch of subcutaneous Keytruda, known as Qlex, and other lifecycle extensions could preserve the drug’s commercial momentum and support exclusivity through 2039. Recent regulatory approvals, pipeline progress and the acquisitions of Terns and Cidara also broaden the company’s oncology and virology prospects. Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep
• Positive Sentiment: Analyst estimates have improved, including Erste Group’s modest increase in its FY2027 EPS forecast to $9.54 from $9.52. Barclays has also forecast strong potential appreciation for MRK, reinforcing the constructive sentiment around the shares. Barclays Forecasts Strong Price Appreciation for Merck & Co., Inc. Stock
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend provides ongoing income support, with a reported annualized yield of about 2.6%.
• Neutral Sentiment: MRK is scheduled to release second-quarter 2026 results before the market opens on August 4. Consensus calls for approximately $16.33 billion in sales and a loss of $0.26 per share, with acquisition costs likely affecting reported earnings. Investors will watch Keytruda demand, Gardasil performance and management’s outlook. Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
• Neutral Sentiment: Merck and Wellcome’s Hilleman Laboratories are preparing an experimental Ebola vaccine for clinical trials. The initiative supports Merck’s public-health profile but is unlikely to materially affect near-term financial results. Merck, Wellcome Partner With Global Health Group to Make Ebola Vaccine for Clinical Trials
• Negative Sentiment: After a roughly 17% rally since its latest quarterly results, MRK may already reflect much of the favorable Keytruda and pipeline news. Analysts characterize its longer-term valuation as justified rather than clearly inexpensive, while Gardasil weakness and the approaching earnings event remain risks. Merck Stock Looks Cheap on Cash Flow but Fair on Earnings

Analyst Ratings Changes

MRK has been the topic of several recent analyst reports. Guggenheim boosted their target price on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, July 13th. UBS Group increased their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Monday, April 13th. Barclays lifted their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an "overweight" rating in a research report on Wednesday. Royal Bank Of Canada reissued an "outperform" rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Finally, Morgan Stanley upped their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an "equal weight" rating in a report on Thursday, July 9th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $134.50.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $130.49 on Friday. The firm's 50 day moving average is $123.17 and its 200-day moving average is $118.46. The stock has a market capitalization of $322.28 billion, a P/E ratio of 36.76, a P/E/G ratio of 5.17 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a 12-month low of $77.53 and a 12-month high of $135.05.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the firm earned $2.22 EPS. The business's revenue for the quarter was up 4.9% on a year-over-year basis. Equities research analysts anticipate that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.'s payout ratio is 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.